Rhinomed Limited announced the interim results in the world first "Rhinoswab for diagnosis of respiratory virus in children" trial, which was carried out by clinical scientists at the Murdoch Children's Research Institute at the Melbourne Children Trials Centre (Royal Children's Hospital.). The preliminary results were presented at a research briefing to both local and international key opinion leaders with the full results to be submitted to a medical journal early in the new year. The trial recruited 254 symptomatic children, aged 4-18 years, who presented at the Respiratory infection Clinic at The Royal Children's Hospital (RCH) Melbourne, Australia. Each child was sampled with the standard of care combined nose and throat swab and the Rhinoswab Junior with the order randomised. Samples were assessed on RT-PCR using an Ausdiagnostics respiratory pathogens 16-well multiplex panel that could identify multiple pathogens including SARS-CoV-2 (2 assays), Influenza A and B, RSV, Rhinovirus/Enterovirus Parechovirus, Parainfluenza 1,2,3,4, Adenovirus groups B,C,E some A,D, Metapneumovirus, Bordetella spp and Mycoplasma Pneumoniae. The objectives of the study were to investigate: The laboratory test performance of the Rhinoswab compared with the current standard of care CTDN swab. The comfort and preference of Rhinoswab compared to the CTDN swab.